
Human papillomavirus (HPV) Associated Cancer - Pipeline Insight, 2024
Description
Human papillomavirus (HPV) Associated Cancer - Pipeline Insight, 2024
DelveInsight’s, “Human papillomavirus (HPV) Associated Cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Human papillomavirus (HPV) Associated Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Human papillomavirus (HPV) Associated Cancer: Overview
Human papillomavirus (HPV) infection is linked with several cancers such as cancer cervix, vagina, vulva, head and neck, anal, and penile carcinomas. Although there is a proven association of HPV with these cancers, questions regarding HPV testing, vaccination, and treatment of HPV-related cancers continue to remain unanswered. The present article provides an overview of the HPV-associated cancers.
Among all human cancers, 15% are caused by viral infections. Human papillomavirus (HPV) accounts for approximately 600,000 cases of cancers of the cervix, oropharyngeal cancers, anal cancers, vulvovaginal and penile cancers, as well as a genital wart and recurrent papillomatosis of the lungs worldwide. HPV has an exclusively intra-epithelial infectious cycle and infects both the cutaneous and mucosal squamous epithelium. HPV type 16 and 18 are the most common oncogenic viruses among the HPVs that cause cancer.
The HPV infects squamous epithelial cells, which have the capacity to proliferate, and get access to basal cell during trauma or abrasion. In the basal cells, HPV infection induces the expression of viral genes that helps in the viral replication. The interaction of HPV with the host cells occurs via surface receptors such as heparin sulfate proteoglycans and alpha 6 integrins. The early proteins E1 and E2 are required for the initiation of replication. The protein E2, being the transcriptional repressor of E6 and E7, controls the expression of E6 and E7.
""Human papillomavirus (HPV) Associated Cancer - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Human papillomavirus (HPV) Associated Cancer pipeline landscape is provided which includes the disease overview and Human papillomavirus (HPV) Associated Cancer treatment guidelines. The assessment part of the report embraces, in depth Human papillomavirus (HPV) Associated Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence in Human papillomavirus (HPV) Associated Cancer R&D. The therapies under development are focused on novel approaches to treat/improve in Human papillomavirus (HPV) Associated Cancer.
- In April 2022, SQZ Biotechnologies focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company’s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.
- In January 2022, HOOKIPA Pharma announced that the first patient has been dosed with HB-200 in combination with pembrolizumab for the treatment of 1st-line advanced/metastatic Human Papillomavirus 16 Positive (HPV16+) squamous cell head and neck cancers (HNSCC) in a Phase 2 arm of the ongoing Phase 1/2 trial (NCT04180215). In addition, the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the Company’s novel immunotherapy candidates, single-vector HB-201 and alternating 2-vector HB-202/HB-201, both in combination with pembrolizumab, for the treatment of 1st-line advanced/metastatic HPV16+ HNSCC.
Human papillomavirus (HPV) Associated Cancer Emerging Drugs
- STP909: Sirnaomics Inc
- RTX-321: Rubius Therapeutics
- BVAC-C: Cellid Co Ltd
- GX-188E: Genexine Inc
- ITI-2000: Immunomic Therapeutics Inc
Further product details are provided in the report……..
Human papillomavirus (HPV) Associated Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Human papillomavirus (HPV) Associated Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Human papillomavirus (HPV) Associated Cancer
Phases
DelveInsight’s report covers around 50+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
Products have been categorized under various Molecule types such as
- Small molecule
- Gene Therapy
- Cell Therapy
- Immunotherapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Human papillomavirus (HPV) Associated Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Human papillomavirus (HPV) Associated Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Human papillomavirus (HPV) Associated Cancer drugs.
Human papillomavirus (HPV) Associated Cancer Report Insights
- Human papillomavirus (HPV) Associated Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Human papillomavirus (HPV) Associated Cancer drugs?
- How many Human papillomavirus (HPV) Associated Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Human papillomavirus (HPV) Associated Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Human papillomavirus (HPV) Associated Cancer?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Human papillomavirus (HPV) Associated Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Turnstone Biologics
- Advaxis
- AstraZeneca
- VLP The Vaccines Company SL
- Voltron Therapeutics Inc
- Rubius Therapeutics
- Inovio Pharmaceuticals
- Bristol-Myers Squibb
- Precigen Inc
- Privo Technologies
- ViciniVax BV
- Avalia Immunotherapies
- BlueSky Immunotherapies
- Cellid Co Ltd
- Cue Biopharma
- Cullinan Oncology
- Genexine
- EyeGene
- Hookipa Pharma
- Immunomic Therapeutics
- ISA Pharmaceuticals BV
- SQZ Biotechnologies
- Key Products
- MG1 HPV
- Axalimogene filolisbac
- MEDI 0457
- HPV Cancer Research Project
- MEDI 0457
- RTX 321
- VGX 3100
- Nivolumab
- PRGN-2009
- PRV111
- Vvax001
- AVA1156 (PREC
- delNS HPV 16
- BVAC-C
- CUE-101
- Jade
- GX-188E
- EG-VAC
- HB-200
- ITI-2000
- ISA101b
- SQZ-PBMC-HPV
Table of Contents
90 Pages
- Introduction
- Executive Summary
- Human papillomavirus (HPV) Associated Cancer: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Human papillomavirus (HPV) Associated Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Axalimogene filolisbac: Advaxis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- PRGN-2009: Precigen PII
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- HB-200: Hookipa Pharma Inc
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- RTX 321: Rubius Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Human papillomavirus (HPV) Associated Cancer Key Companies
- Human papillomavirus (HPV) Associated Cancer Key Products
- Human papillomavirus (HPV) Associated Cancer - Unmet Needs
- Human papillomavirus (HPV) Associated Cancer - Market Drivers and Barriers
- Human papillomavirus (HPV) Associated Cancer - Future Perspectives and Conclusion
- Human papillomavirus (HPV) Associated Cancer Analyst Views
- Human papillomavirus (HPV) Associated Cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.